Citius Oncology regains Nasdaq minimum bid price compliance

CITIUS ONCOLOGY, INC.

Received Nasdaq compliance notice on June 26, 2025, for Listing Rule 5550(a)(2).
Common stock closing bid price was $1.00+ for 12 consecutive trading days (June 6–24, 2025).
Nasdaq considers the bid price deficiency matter closed.
Company avoids delisting; its common stock remains listed on Nasdaq Capital Market.
Ticker CTOR; compliance regained after previous bid price shortfall.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.